IM Cannabis (IMCC) Liabilities from Discontinued Operations (2022)
IM Cannabis' (IMCC) quarterly Liabilities from Discontinued Operations came in at 33440104.0 in Q3 2022.
IM Cannabis (IMCC) Liabilities from Discontinued Operations (2022) Analysis & Trends
IM Cannabis' Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 33440104.0 for Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 33.44 Mn |
| Sep 30, 2022 | 33.44 Mn |